Skip to main content
. Author manuscript; available in PMC: 2024 May 4.
Published in final edited form as: Nat Biotechnol. 2023 Jan 2;41(6):845–857. doi: 10.1038/s41587-022-01539-0

Fig. 1 |. A 96-well-plate-based platform for comprehensive proteome analysis of drug MOA.

Fig. 1 |

a, Overview of screening scheme, starting with HCT116 cells growing in 96-well plates. Deep proteome analysis in duplicate is performed using TMT sample multiplexing after 24-h treatments. b, Clinical stage of compounds from the MOA library at time of annotation. c, Proteome depth for each of the 875 compounds in the dataset. d, Representative proteome fingerprint for the molecular glue pomalidomide showing replicate measurements for downregulated proteins—displayed as log2(FC) (pomalidomide versus DMSO).